PAR:OSE

OSE Immunotherapeutics S.A. · PAR · Healthcare · EUR · FY for 2025

Figures on this page computed 2026-11-08 13:17 UTC

Last close

n/aEUR

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-1439.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
-1303.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed

Growth is the furthest below its sector's middle: 0.07 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

All from 100

lens 2 of 9

Sales

684

2016-12-31 to 2025-12-31100 at the start684

Sales: 100.00 on 2016-12-31 to 683.81 on 2025-12-31, up 584%.

Profit

-182

2016-12-31 to 2025-12-31100 at the start-182

Profit: 100.00 on 2016-12-31 to -182.43 on 2025-12-31, down 282%.

Shares in issue

164

2016-12-31 to 2025-12-31100 at the start164

Shares in issue: 100.00 on 2016-12-31 to 164.19 on 2025-12-31, up 64%.

Sales is at 684, Profit is at -182, Shares in issue is at 164, against 100 in 2016.

Sales is at 684, Profit is at -182, Shares in issue is at 164, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100684
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Profit, where the first year is 100-182
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Shares in issue, where the first year is 100164
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR